Reported 1 day ago
Mizuho has raised its price target for Neumora Therapeutics (NASDAQ: NMRA) from $4 to $5 while keeping an Outperform rating. This change follows the announcement of a Phase 1 study for NMRA-861, a promising treatment for schizophrenia. The firm anticipates that NMRA-861 could achieve significant sales by 2037, reflecting a positive outlook for the company, despite acknowledging that other AI stocks may present more upside potential.
Source: YAHOO